Genrui Biotech

Executive Summary

Genrui Biotech, founded in 2004 and headquartered in Shenzhen, China, is a leading private in-vitro diagnostics (IVD) company with 500-1000 employees. The company develops, manufactures, and markets a comprehensive portfolio of diagnostic instruments and reagents, including hematology analyzers, specific protein analyzers, point-of-care testing (POCT) devices, and chemistry analyzers. Its integrated total IVD solutions target clinical laboratories, with a significant product line addressing COVID-19 testing. Genrui's proprietary technology and broad product range position it as a key player in China's rapidly growing IVD market, driven by increasing demand for accessible and accurate diagnostic tools. The company's focus on innovation and cost-effective solutions supports its expansion in both domestic and international markets, though details on funding and valuation remain undisclosed as a private entity.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Fully Automated Hematology Analyzer70% success
• Q3 2026Regulatory Approval for Expanded Infectious Disease POCT Panel60% success
• TBDStrategic Partnership with Major Chinese Hospital Network50% success